The inhibitor antibody response is more complex in hemophilia a patients than in most nonhemophiliacs with factor VIII autoantibodies

Blood

Volumn 89, Issue 10, 1997, Pages 3663-3671

  Prescott, Richard ^b   Nakai, Hiroaki ^b   Saenko, Evgueni L ^b   Scharrer, Inge ^b   Nilsson, Inga Marie ^b   Humphries, John E ^b   Hurst, Deborah ^b   Bray, Gordon ^b   Scandella, Dorothea ^a  

^a AMERICAN RED CROSS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BLOOD CLOTTING FACTOR 8;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BLOOD CLOTTING; COMPLEX FORMATION; GENE MUTATION; GENETIC DISORDER; GENETIC RECOMBINATION; HEMOPHILIA A; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN;

EID: 0030926974     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.10.3663     Document Type: Article

References (27)

1. Hoyer LW, Scandella D: Factor VIII inhibitors: Structure and function in autoantibody and hemophilia A patients. Semin Hematol 31:1, 1994
2. Tuddenham EGD, Schwaab R, Seehafer J, Millar DS, Gitschier J, Higuchi M, Bidichandani S, Connor JM, Hoyer LW, Yoshioka A, Peake IR, Olek K, Kazazian HH, Lavergne J-M, Gianelli F, Antonarakis SE, Cooper DN: Haemophilia A: Database of nucleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 22:3511, 1994
3. Shapiro SS, Hultin M: Acquired inhibitors to coagulation factors. Semin Thromb Hemost 1:336, 1975
4. Vehar GA, Keyt B, Eaton D, Rodriguez H, O'Brien DP, Rotblat F, Oppermann H, Keck R, Lawn RM, Capon DJ: Structure of human factor VIII. Nature 312:337, 1984
5. Lollar P, Parker CG: Subunit structure of thrombin-activated porcine factor VIII. Biochemistry 28:666, 1989
6. a. J Biol Chem 267:13246, 1992
7. Burke RL, Pachl C, Quiroga M, Rosenberg S, Haigwood N, Nordfang O, Ezban M: The functional domains of coagulation factor VIII:C. J Biol Chem 261:12574, 1986
8. Toole JJ, Pittman DD, Orr EC, Murtha P, Wasley LC, Kaufman RJ: A large region (≈95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity. Proc Natl Acad Sci USA 83:5939, 1986
9. Scandella D, Mattingly M, Prescott R: A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies which bind to A2. Blood 82:1767, 1993
10. Scandella D, Kessler C, Esmon P, Hurst D, Courter S, Gomperts E, Felch M, Prescott R, the Recombinate and Kogenate Study Groups: Epitope specificity and functional characterization of factor VIII inhibitors, in Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GCI (eds): Inhibitors to Coagulation Factors. New York, NY, Plenum, 1995, p 47
11. Scandella D, Mattingly M, de Graaf S, Fulcher CA: Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74:1618, 1989
12. Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS: A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain. Blood Coagul Fibrinolysis 1:9, 1990
13. Fulcher CA, de Graaf Mahoney S, Zimmerman TS: FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69:1475, 1987
14. Tiarks C, Pechet L, Anderson J, Mole JE, Humphreys RE: Characterization of a factor VIII immunogenic site using factor VIII synthetic peptide 1687-1695 and rabbit anti-peptide antibodies. Thromb Res 65:301, 1992
15. Scandella D, Gilbert GE, Shima M, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Saenko E: Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino aicds 2248-2312 which overlap a phospholipid binding site. Blood 86:1811, 1995
16. Bray GL, Gomperts ED, Courter S, Gruppo R, Gordon EM, Manco-Johnson M, Shapiro A, Scheibel E, White III G, Lee M, Recombinate Study Group: A multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. Blood 83:2428, 1994
17. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, and the Kogenate Previously Untreated Patient Study Group: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 328:453, 1993
18. Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW: A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 67:665, 1992
19. Healey JF, Lubin IM, Saenko EL, Hoyer LW, Scandella D, Lollar P: Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270:14505, 1995
20. Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, van Eys J: A more uniform measurement of factor VIII inhibitors. Thromb Diathes Haemorrh 34:869, 1975
21. Kaufman RJ, Davies MV, Pathak VK, Hershey JWB: The phosphorylation state of eucaryotic initiation factor 2 alters translational efficiency of specific mRNAs. Mol Cell Biol 9:946, 1989
22. 365 of the factor VIII heavy chain. J Clin Invest 82:123, 1988
23. Fulcher CA, Lechner K, de G.Mahoney S: Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 72:1348, 1988
24. Gilles JG, Saintremy JMR: Healthy subjects produce both anti-factor VIII and specific anti-idiotypic antibodies. J Clin Invest 94:1496, 1994
25. Arai M, Scandella D, Hoyer LW: Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 83:1978, 1989
26. Shima M, Nakai H, Scandella D, Tanaka I, Sawamoto Y, Kamisue S, Morichika S, Murakami T, Yoshioka A: Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 91:714, 1995
27. Lubin IM, Healey JF, Scandella D, Runge MS, Lollar P: Elimination of a major inhibitor epitope in factor VIII. J Biol Chem 269:8639, 1994